Overview

‘Twenty-first Century Drug Discovery – an Expanding Landscape’ follows on from the author’s previous book ‘The Science and Business of Drug Discovery – Demystifying the Jargon’, published by Springer as a second edition in 2020. While many of the key scientific and commercial features of drug discovery described in the latter are essentially unchanged since publication, the underlying science has advanced rapidly thereby presenting a broad landscape of opportunities for biopharmaceutical discovery in the twenty-first century and beyond. However, these wide-ranging and complex discovery opportunities are difficult to convey in a short period of time. This book overcomes the problem by giving readers time to study the relevant material at their leisure.  Starting with a short overview of the current technical and commercial background to drug discovery and development, the book focuses on the discovery of novel targets and therapeutic agents. The latter are no longer just small molecules, but include engineered proteins, microbes and immune cells created as a result of advances in molecular cell biology and computational methods, among others. These discovery activities are presented as part of a group of ‘systems’ under the headings of Genetics, Cell Biology, Microbiome, Immune and Nervous Systems, none of which are mutually exclusive and all of which depend upon lab-based and computational technologies. These technologies are covered in some detail, highlighting in particular, single molecule and cell analysis, selective drug target degradation and machine learning.

Full Product Details

9783031939488

Table of Contents

Reviews

Author Information

Dr. Edward D. Zanders has over 30 years’ experience as a scientist and research manager in both a major pharmaceutical company and smaller biotechnology organizations. He has been involved in research management at a senior level and has been responsible for a number of drug discovery programmes for diseases such as asthma and rheumatoid arthritis. He has also published extensively on subjects ranging from biochemistry and immunology to computer-aided drug design and the application of online networking to drug discovery. More recently he has written about drug targets in the human genome and a survey of drug discovery for glioblastoma. In 2004 he founded PharmaGuide Ltd, a training and consultancy company that delivers courses on the drug discovery industry to various professional groups including scientists, technology transfer executives, recruiters and technical translators. It is through delivering these courses that he has been able to highlight emerging areas of drug discovery that show great promise for the future treatment of disease. 

Tab Content 6

Customer Reviews

Recent Reviews

Countries Available